139 related articles for article (PubMed ID: 30160364)
1. Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients.
Suttorp M; Metzler M; Millot F; Shimada H; Bansal D; Günes AM; Kalwak K; Sedlacek P; Baruchel A; Biondi A; Hijiya N; Schultz KR; Schrappe M
Pediatr Blood Cancer; 2018 Dec; 65(12):e27431. PubMed ID: 30160364
[TBL] [Abstract][Full Text] [Related]
2. What Happens When Imatinib Goes Generic?
McDougall J; Ramsey SD; Radich J
J Natl Compr Canc Netw; 2016 Feb; 14(2):128-31. PubMed ID: 26850483
[No Abstract] [Full Text] [Related]
3. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
[TBL] [Abstract][Full Text] [Related]
5. A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets.
Arora R; Sharma M; Monif T; Iyer S
Cancer Res Treat; 2016 Jul; 48(3):1120-9. PubMed ID: 26875198
[TBL] [Abstract][Full Text] [Related]
6. Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.
Lyman GH; Henk HJ
JAMA Oncol; 2020 Dec; 6(12):1969-1971. PubMed ID: 33001149
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
Ostojic A; Sertic D; Roncevic P; Peric Z; Granic P; Matic N; Basic-Kinda S; Serventi-Seiwerth R; Radman I; Zadro R; Nemet D
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):472-6. PubMed ID: 27245313
[TBL] [Abstract][Full Text] [Related]
8. Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.
Klil-Drori AJ; Yin H; Azoulay L; Harnois M; Gratton MO; Busque L; Assouline SE;
Haematologica; 2019 Jul; 104(7):e293-e295. PubMed ID: 30630987
[No Abstract] [Full Text] [Related]
9. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475
[TBL] [Abstract][Full Text] [Related]
11. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Conti RM; Padula WV; Larson RA
Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
[TBL] [Abstract][Full Text] [Related]
12. The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
Uyanik MS; Pamuk GE; Maden M; Merev E; Cevik G; Uyanik V; Umit EG; Demir AM; Akker M
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26594025
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
14. Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
Awidi A; Abbasi S; Alrabi K; Kheirallah KA
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e55-e61. PubMed ID: 28844599
[TBL] [Abstract][Full Text] [Related]
15. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.
Jabbour EJ; Mendiola MF; Lingohr-Smith M; Lin J; Makenbaeva D
J Med Econ; 2019 Nov; 22(11):1113-1118. PubMed ID: 31074658
[No Abstract] [Full Text] [Related]
16. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511.
Yokoo M; Kubota Y; Tabe Y; Kimura S
Biol Pharm Bull; 2015; 38(3):411-6. PubMed ID: 25757922
[TBL] [Abstract][Full Text] [Related]
17. The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.
Das L; Gitlin M; Siegartel LR; Makenbaeva D
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):133-140. PubMed ID: 28287008
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.
Geissler J; Sharf G; Cugurovic J; Padua R; Narbutas Š; Remic M; Venkatesh V
Leukemia; 2016 Dec; 30(12):2396-2397. PubMed ID: 27484147
[No Abstract] [Full Text] [Related]
19. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
20. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
[Next] [New Search]